For a long time, the South Korean stock market was like a “fortress” to global retail investors. While institutional giants played their games, individual investors in the US or Europe had to settle for broad ETFs like EWY, often missing out on the explosive growth of individual gems in the K-tech or K-defense sectors. But … Read more
NXST analysis: 3.77% yield, 27% 5-year dividend growth, and a significant 73% margin of safety. Discover why current one-time noise creates a ‘Strong Buy’ opportunity.
Deep dive into Apple’s (AAPL) recent earnings surge and AI strategy. Currently 15% overvalued vs. $241 fair price. Evaluating its 22-year dividend growth and investment outlook.
Earnings Analysis : Slight Revenue Growth and EPS Beat (In Line with Market Expectations) 📊 Earning Summary Metric Current Quarter QoQ Change vs Consensus (Est) Revenue $85.14B +3.4% +3.6% Net Income $4.89B -32.6% +15.1% EPS $1.16 -32.2% +15.4% Revenue grew 2.5% YoY, driven by higher oil/gas prices and expanded refining operations. EPS decreased 34.1% YoY … Read more
Altria (MO) Q1 Earnings Analysis: Adjusted EPS of $1.32 beats consensus by 5.6%. Strong pricing power and growth in on! PLUS confirm resilient fundamentals.
Merck’s (MRK) latest quarterly results saw EPS turn negative due to a massive charge from business development (BD) activities. However, beneath the surface, core product performance and future growth strategies remain more robust than ever, defying initial market concerns. Earnings Summary (Actual vs. Expected) Metric Actual (Current) QoQ Change Vs. Consensus Revenue $ 16.29B -0.7% … Read more
Deep dive into Alphabet’s Q1 2026 earnings. Cloud revenue grew 63% YoY, driven by GenAI infrastructure. Analysis of TPU strategy and Gemini subscription models.
Visa’s Q1 2026 results show strong double-digit growth. Analysis of the new Visa CLI for AI agent payments and expansion of blockchain settlement systems.
Merck (MRK) deep dive: 3.08% forward yield, 21-year dividend growth streak, fair value $141.8 vs. current $111.8. A Strong Buy with a 26% margin of safety. Plan B analysis.
Deep dive into AbbVie’s Q1 2026 results. How Skyrizi and Rinvoq are successfully replacing the revenue gap left by Humira’s patent expiration.